Subscribe Sign In Register

Biomarin Pharmaceutical

Martin Shkreli, Chief Investment Officer of MSMB Capital Management
Portfolio
Pharmaceutical Companies Gird for Drug-Price Reckoning
Uproar over suddenly hiked-up medications may not crush health care stocks for long, but it does force the industry to justify value.
Kaitlin Ugolik
October 8, 2015
tourbillon-thumbnail.jpg
Premium
Tourbillon Thrives on a Heady Mix of PR and Performance
Jason Karp’s still-young hedge fund firm generates big numbers with an unusual long-short strategy — and a CIA interrogator.
Stephen Taub
June 9, 2015